August 14, 2014 | RedHill BioPharma, an emerging Israeli biopharmaceutical company focusing on the treatment of inflammatory and gastrointestinal diseases, has acquired an option for a Phase II pancreatic cancer drug RP101. RedHill acquired the cancer-treating drug from Dresden, Germany-based company RESprotect GmbH, a spin-off of the Fraunhofer Society. According to RedHIll, RP101 has completed Phase I and II clinical trials and has been granted the Orphan Drug designation for the treatment of pancreatic cancer by the United States Food & Drug Administration (FDA) and the European Medicines Agency (EMA).
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

$10M For Cyber Company That Protects Small Businesses
January 31, 2023

Phone-Block Technology For School Bus Drivers
January 31, 2023

Israeli Patients Can Now WhatsApp Their Doctor
January 31, 2023

People With Autism Experience Higher Intensity Pain
January 30, 2023
Facebook comments